Daxor Announces St. Francis Medical Center of Honolulu, HI Acquires Blood Volume Analyzer BVA-100
Posted on: Tuesday, 2 May 2006, 09:01 CDT
Daxor Corporation (AMEX:DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from the St. Francis Medical Center of Honolulu, Hawaii.
St. Francis Medical Center is a comprehensive 308-bed healthcare facility providing tertiary care. As part of the St. Francis Healthcare System of Hawaii, St. Francis Medical Center is the host to four centers of excellence: Heart, Transplant, Oncology and Neurology. Additional services include a full range of general acute and medical/surgical services. In addition, diagnostic support services such magnetic resonance imaging (MRI), P.E.T. imaging, radiological services, mammography, CT scan, ultrasound, nuclear medicine and angiography are offered.
As a leader in establishing healthcare services for the people of Hawaii, St. Francis Health System has grown from a 50-bed hospital to a five-entity corporation. The System is comprised of: St. Francis Medical Center; St. Francis Medical Center-West; St. Francis Community Health Services; St. Francis Healthcare Foundation; St. Francis Healthcare Enterprises, Inc.; and Residential Care Community.
Dr. Larry Kaufman, St. Francis Medical Center's Critical Care Hospitalist and Intensive Care Specialist, commented that, "The recent data concerning a measured blood volume is quite stimulating and we look forward to contributing to the growing results of the utility of blood volume analysis in the intensive care unit." Daxor's BVA-100 will reside within the nuclear medicine department, and will be utilized in diagnosing blood volume derangements in various clinical conditions, but most specifically in patients with septic shock; following coronary artery by-pass surgery; and end stage kidney dialysis patients. This will be Daxor's second BVA-100 in Hawaii and the first BVA-100 in which end stage kidney dialysis patients will benefit from a measured blood volume prior to dialysis treatment.
"End stage dialysis patients have dramatic blood volume alterations during dialysis. A measured blood volume is a logical approach to provide a more precise treatment and potentially improved clinical outcomes," noted Dr. Joseph Feldschuh, Daxor's C.E.O. and Chief Scientific Officer.
Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with a single use diagnostic kit.
For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com, or contact Stephen Feldschuh, 212-330-8515 (VP of Operations) stephen@daxor.com or Diane Meegan, 212-330-8512 (Investor Relations) dmeegan@daxor.com.
Source: Business Wire
Related Articles
- Stream Global Services Named in 2009 Global Services 100
- Neoris Named 'Leader - IT Service Provider in Latin America' On Global Services 100 List
- North Carolina's Center For Advanced Medicine & Clinical Research Celebrates Opening of New LKN Medical Spa and Rejuvenation Center
- CVCTA Education, AMIGenics and Nevada Imaging Centers Partner to Introduce the First Dynamic Volume CT Education Center
- Medical Institutional Services Holdings Signs Contract With Doctors Family Medical Centers
- Comcast Unveils New 200-Employee Business Services Support Center
- Rural/Metro Wins Bid to Continue Medical Transportation Services to University of Colorado Hospital
- Hispanic Teleservices Corporation Debuts in the Global Services 100
- Luxoft Named to the 2006 ''Global Services 100'' List of Most Innovative Technology Services Companies
- SIDMAP Provides Metabolic Phenotyping Services to Researchers at Harvard Medical School's Joslin Diabetes Center and the University of Utah
 |
 |
User Comments (0)
RSS Feeds